Cirsium Biosciences Advances Plant-Based AAV Platform and Builds Scale-Up Infrastructure

Cirsium Biosciences is a private biotechnology company developing a plant-based manufacturing platform for adeno-associated virus (AAV) gene therapies, and this is a weekly summary of its notable news. Over the past week, the company emphasized its dual focus on scaling AAV production and deepening in-house expertise in plant biology and process optimization.

Cirsium reiterated that its platform leverages stressed plant leaves as highly productive hosts for AAV expression, noting that maximal yield does not necessarily correlate with visually healthy plants. This biology-first perspective is intended to support efficient biomass production and, if validated at scale, could underpin lower cost-of-goods for gene therapy developers.

The company detailed progress on its proprietary “infiltrator” hardware, which has evolved from a manual 2022 prototype handling five plants to an automated system targeting batches of more than 100 plants. It also showcased an end-to-end AAV workflow from tray seeding and plant growth through post-infiltration expression and homogenized biomass, underscoring a defined, repeatable process.

Automation is a core theme, with Cirsium now implementing automated tray seeding to reduce setup times from hours to minutes while maintaining precision. These initiatives are aimed at boosting throughput, consistency, and scalability, potentially lowering labor intensity and supporting more competitive manufacturing economics as demand for AAV vectors grows.

In parallel, the company strengthened its leadership bench with a Senior Director of Quality Assurance bringing more than 35 years of industry experience and a Senior Director of Operations to oversee operational, financial, and technology infrastructure. Additional hires, including a Facility Manager and Lab Aide, are intended to support vertical farms, integrated processes, and day-to-day laboratory workflows.

Cirsium also highlighted internal R&D talent, including Research Associate II Natalie Gonzalez, who is focused on optimizing agrobacterium production and plant input conditions, and Scientist I Matthew Kohls, who brings roughly three decades of life sciences experience. This emphasis on in-house expertise signals active investment in functional genomics, trait characterization, and process optimization to refine the plant-based platform.

Strategically, the company used World Health Day messaging to position itself around the global challenge of scalable access to AAV gene therapies. Cirsium framed manufacturing capacity and deployment, rather than scientific feasibility, as key constraints and signaled an intent to support developers, CDMOs, and other ecosystem participants through platform and partnership-driven models.

Taken together, the week’s updates point to a company focused on technical scale-up, automation, and quality infrastructure rather than near-term commercial milestones. These developments may enhance Cirsium’s ability to compete as an enabling player in the AAV supply chain, laying groundwork for future partnerships and commercialization opportunities in gene therapy manufacturing. Overall, it was a week characterized by operational progress and team-building in support of long-term platform execution.